Nurix Therapeutics, Inc. NRIX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$295.28M-11.7% | -$264.46M-8.0% | -$244.79M-18.1% | -$207.32M+0.5% | -$208.4M-7.7% | ||
| $8.59M-1.8% | $8.74M-4.7% | $9.17M-3.8% | $9.54M-0.9% | $9.62M+3.3% | ||
| $38.65M+1.8% | $37.97M+1.5% | $37.39M+2.8% | $36.37M+4.4% | $34.83M+2.7% | ||
| -$260.29M-4.3% | -$249.47M-8.3% | -$230.38M-7.1% | -$215.18M-12.2% | -$191.72M-11.1% | ||
| $11.56M-17.4% | $14M+27.6% | $10.98M+3.4% | $10.61M+7.5% | $9.87M+6.5% | ||
| -$1.51M-101% | $147.85M+2,110% | $6.69M+110% | -$65.12M+75.7% | -$267.69M-3.9% | ||
| $257.14M+7.8% | $238.64M+17.5% | $203.16M-18.0% | $247.77M-49.0% | $485.52M0.0% | ||
| -$4.65M-103% | $137.03M+767% | -$20.54M— | —— | —— | ||
| -$271.85M-3.2% | -$263.47M-9.2% | -$241.36M-6.9% | -$225.79M-12.0% | -$201.59M-10.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nurix Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.